S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%
Next Bullish Trade
Sign in
AZN

AstraZeneca PLC AZN

$168.90 -0.39 (-0.23%)
Pullback · -1.77σ
Mkt cap $262.8B
P/E 25.3
Day $167.16 – $170.31
52wk $164.45 – $212.71
Avg vol
Beta
Div yld
Next earnings

Quick read

Plain English

AstraZeneca PLC is a healthcare company listed in the US.

AZN last traded at $168.90, down 0.2% on the day; that's in the lower part of its 52-week range ($164.45–$212.71). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 39), the trend is quiet (ADX 21), and trading is light at 0.7× normal volume. On the business side, revenue is growing 12% year over year and the business keeps about 11 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI
39
0–100 · <30 oversold
Trend strength · ADX
21
>25 = strong trend
Volume vs avg
0.74×
1× = average
Stretch from avg
-1.8 ATR
− below · + above
Zone touches
0
tests of this zone
Suggested hold
3–30
bars (≈ days)
Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth
+12.5%
year over year
Free-cash-flow margin
11.2%
cash kept per $ of sales
Debt / equity
0.72
lower = less leveraged
P/E ratio
25.3
price ÷ yearly profit

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $97.97 (fair range $85–$138); today's price sits 72% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)
$97.97
Fair-value range
$84.58 – $137.96
Margin of safety
-72%
Verdict
Overvalued
Accounting quality Weak
  • ✓ Positive retained earnings
  • ✓ Gross margin 82% (pricing power)
  • ⚠ Debt exceeds cash
  • ⚠ Quick ratio 0.59 (fragile)
  • ⚠ Receivables growing faster than revenue
  • ⚠ Inventory growing faster than revenue

Price implies ~21% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

AZN is a $262.8 billion company, priced at 25× last year's earnings, and the stock is trading near the bottom of its 52-week range.

Mkt cap $262.8B
P/E ttm 25.3
Fwd P/E
Beta
Day range $167.16 – $170.31
52w range $164.45 – $212.71
Avg vol
RSI(2) 48.0
ROE
Net mgn
FCF mgn 11.2%
Debt/Eq 0.72
Div yld
Sector Healthcare
Industry Drug Manufacturers - General
Next earn
52-week range · today's price
$164.45$212.71

More on AZN